Award
Definitive Contract #75F40126C00112
Advanced Clinical Outcome Assessment Research Contract Awarded to Duke University
Buyer
Food and Drug Administration
Award Amount
$1,456,427.00
Ceiling
$1,456,427.00
Awarded
September 30, 2026
Period of Performance
Sep 30, 2026 – Sep 29, 2028
Identifier
75F40126C00112
NAICS
541714
This definitive contract has been awarded to Duke University, a leading academic and research institution, for advanced research and development in regulatory science focused on core clinical outcome assessment. The contract supports a critical grant program aimed at improving methodologies used to evaluate clinical outcomes, which are essential for regulatory decision-making and advancing healthcare. This multi-year agreement emphasizes innovative scientific investigations to enhance public health policies and medical product evaluations. The scope includes comprehensive research and development activities within regulatory science, conducted in Durham, North Carolina, where Duke University is based. Awarded through a competitive broad agency announcement, this contract represents a significant investment in cutting-edge clinical research with implications for the public sector and medical industries.
Description
EO14398 - BROAD AGENCY ANNOUNCEMENT (BAA) FY26C1IP3 - ADVANCED RESEARCH AND DEVELOPMENT OF REGULATORY SCIENCE - CORE CLINICAL OUTCOME ASSESSMENT GRANT PROGRAM